The United Kingdom and the United States have hammered out a important trade agreement that will guarantee zero tariffs on British pharmaceutical exports entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase funding on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that import taxes on these vital goods will stay at nothing for a duration of 36 months.
This agreement is in response to earlier warnings to significantly raise duties on patented drug products, with increases floated reaching 100%.
"This agreement between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and brings much-needed fairness to American-British medicine commerce," an announcement declared.
Trade Impact
Drugs constitute one of the Britain's biggest exports to the America, which is by far the biggest buyer for major companies like GSK and AstraZeneca.
Trade data show that in the 12 months leading up to September, the UK sold medicines valued at billions to the US. This value represented a significant portion of total UK exports in that span.
"This deal safeguards employment, boosts capital expenditure and facilitates the UK to become a worldwide center for biotech and pharma," a minister commented.
Specific UK Commitments
The deal includes several specific changes from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to increase overall NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to control costs will be limited at fifteen percent. In the past, refunds were more than 20%.
Recent Tensions
This agreement comes amid a ongoing row between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
These tensions were intensified by arguments that American customers were charged a premium for the equivalent treatments than consumers in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been halted or abandoned, while substantial funding commitments have been announced toward US facilities.
One official acknowledged that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had declined as a proportion of its total funding over the last ten years.
